Skip to main content

Table 1 General characteristics of study participants at baseline study

From: The effects of probiotic supplementation on metabolic status in type 2 diabetic patients with coronary heart disease

 

Placebo group (n = 30)

Probiotic group (n = 30)

P 1

Age (year)

61.8 ± 9.8

60.7 ± 9.4

0.64

Familial history (%)

10 (33.7)

11 (36.7)

0.78†

Height (cm)

163.2 ± 7.1

162.5 ± 7.2

0.72

Weight at study baseline (kg)

78.2 ± 11.8

80.2 ± 15.3

0.57

Weight at end-of-trial (kg)

78.2 ± 12.0

80.2 ± 15.3

0.56

Weight change (kg)

− 0.03 ± 1.1

0.04 ± 1.0

0.78

BMI at study baseline (kg/m2)

29.3 ± 4.1

30.3 ± 5.2

0.42

BMI at end-of-trial (kg/m2)

29.3 ± 4.1

30.3 ± 5.2

0.41

BMI change (kg/m2)

− 0.01 ± 0.4

0.06 ± 0.4

0.81

Smoking (%)

3 (10.0)

3 (10.0)

1.00†

Aspirin 80 mg (%)

30 (100)

30 (100)

1.00†

Statin (%)

30 (100)

30 (100)

1.00†

Insulin therapy (%)

8 (26.7)

7 (23.3)

0.76†

Antidiabetic drugs (%)

 Monotherpy

16 (72.7)

17 (70.8)

 

 Combination therapy

6 (27.3)

7 (29.2)

0.88†

Hypertension (%)

22 (73.3)

23 (76.7)

0.76†

ACEI/ARB drugs (%)

30 (100)

30 (100)

1.00†

Blocker drugs (%)

 β-blocker

28 (93.3)

29 (96.7)

 

 Calcium channel blocker

2 (6.7)

1 (3.3)

0.55†

Duration of DM (year)

6.8 ± 2.2

6.6 ± 1.9

0.61

Duration of CHD (year)

9.5 ± 2.2

9.3 ± 1.6

0.78

  1. Data are means ± SDs
  2. ACEI Angiontensin converting enzymes inhibitors, ARB Aldosterone receptor blockers, CHD coronary heart disease, DM diabetes mellitus
  3. 1Obtained from independent t-test
  4. †Obtained from Pearson Chi square test